Navigation Links
Alpha in Medical Technology

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

... (TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and ... prostate and bladder neck, which is mediated by alpha 1A adrenoreceptors," said Leonard S. Marks, MD, ... semen), an expected treatment effect of selective alpha blockers, which occurred in 28 percent of men ...

Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms

... (AUA) showing that generic substitutes for alpha blockers and 5-alpha reductase inhibitors ... weeks, the study tested 212 men taking branded alpha blockers or 5-ARIs with an average age of 64, who ... dysfunction (3.6 percent) for those switching alpha blockers, and ejaculatory dysfunction (4.7 ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... disease previously untreated with interferon alpha and who are at least 18 years of age. The ... DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS alpha interferons, including PEGINTRON, may cause or ... and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... disease previously untreated with interferon alpha and who are at least 18 years of age. The ... DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS alpha interferons, including PEGINTRON, may cause or ... and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... the company's new, uniquely selective alpha blocker for the treatment of the signs and ... antagonist that binds with high affinity to the alpha 1a receptors concentrated in the prostate, ... in BPH symptoms. The binding affinity for the alpha 1B receptors that regulate smooth muscle ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... who failed previous treatment with combination alpha interferon/ribavirin were retreated with ... previously treated with nonpegylated or pegylated alpha interferon and ribavirin combination therapy, ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON, may cause or ...

ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity

... Phase I/IIa clinical development of its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). ... by episodes of local inflammation and thus, TNF alpha represents a highly promising target. TNF alpha is excessively generated in OA by chondrocytes, ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... have not been previously treated with interferon alpha and who are at least 18 years of age. ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... of the hair) is also often associated with alpha interferons including PEGINTRON. ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

... whether or not silodosin -- an investigational alpha blocker -- would prolong the QT interval on an ... Silodosin is a novel, highly uroselective alpha (1A)-adrenoceptor antagonist originally developed ... markets. Silodosin preferentially binds to the alpha (1A) receptors in the prostate and bladder neck ...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

... failed prior treatment with interferon alpha (pegylated or non-pegylated) and ribavirin ... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ...

Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia

... Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate and ... The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ ...

Schering-Plough Reports Top-Line Results of the IDEAL Study

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response

... have not been previously treated with interferon alpha and who are at least 18 years of age. PEGINTRON ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases

... is developing EVP6124, a selective, orally active alpha 7 Nicotinic Acetylcholine Receptor Agonist for ... to begin in early 2008. It is anticipated that alpha 7 agonist compounds will improve cognitive ... Senior Director and program executive for the alpha 7 initiative. Dr. Gawryl has more than 20 years ...

European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy

... and ribavirin combination therapy or interferon alpha monotherapy did not result in a sustained ... who failed previous treatment with combination alpha interferon/ribavirin therapy were retreated ... to one or more courses of interferon alpha plus ribavirin combination therapy (HCV-RNA ...

Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years

... treatment with AVODART (dutasteride) and the alpha blocker tamsulosin provides significantly greater ... belongs to a class of medicines known as 5 alpha reductase inhibitors (5 ARIs), which shrink the prostate over time. Tamsulosin is an alpha blocker, a class of medicines that relaxes ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS (R) (Peginterferon alfa-2a), may cause ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

... targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use. ... antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, ...

Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings

... hormone products currently on the market, which are both ER beta and ER alpha agonists that have been shown to increase the risk for breast and uterine ... the increased risk of breast and uterine cancers is associated with ER alpha activation and that ER beta blocks the growth promoting effects on breast ...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

... disease and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

... that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms ... The data suggest that based on standard regimens for each of the TNF alpha blockers for CD, CIMZIA may be less costly than the two biologics ...

Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin

... II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from ... antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, ...

New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer

... barrier where it affects the brain's neurotransmitters, and increases alpha brain-wave activity. This alpha brain rhythm is known to induce a calmer, yet more alert, state of mind. A ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

... . Important Safety Information alpha interferons, including PEGINTRON(TM), may cause or aggravate fatal or ... events have been observed in patients treated with interferon alpha therapies, including PEGINTRON(TM). Full prescribing information in the ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... PRODUCTS: ON TRACK TO COMMERCIALIZATION Albuferon(R) (albumin-interferon alpha 2b), a novel long-acting form of interferon alpha for the treatment of chronic hepatitis C At the 900-mcg dose now being ...

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C

... disease and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

... of agents that inhibit the pathway at the level of PI3-K, particularly the alpha isoform. Such agents are expected to inhibit proliferation and overcome ... when it secured a collaboration with Genentech in relation to its PI3-K alpha program. The company also has proprietary, unpartnered program targeting ...

Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)

... About Albuferon Albuferon is a novel, longer-acting form of interferon alpha that was created using the proprietary HGS albumin-fusion technology. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a broad ...

Roche responds to announcement of 'IDEAL' hepatitis C trial results

... disease and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS (Peginterferon alfa-2a), may cause or ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders

... Serono is a leader in fertility treatments, with Gonal-f (R) (follitropin alpha for injection), Luveris (R) (lutropin alfa for injection) and Ovidrel (R) Prefilled Syringe (choriogonadotropin alpha injection). The company has strong market positions in neurodegenerative ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

... most comprehensive Phase 3 development program to date for an anti-TNF- alpha biologic therapy. With ongoing studies for the treatment of rheumatoid ... most comprehensive Phase 3 development program to date for an anti-TNF- alpha biologic therapy. With ongoing studies for the treatment of rheumatoid ...
Other Contents
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/19/2014)... 2014 Eufaula, Oklahoma, located just 9 ... the state’s largest lake with more than 600 miles ... to a little more than 3,000 residents, hosted its ... the 6th of December. , Featuring Santa, Christmas lights ... Eufaula on Main Street. Narconon Arrowhead’s parade float ...
(Date:12/19/2014)... An evening dress is perfect for any occasion and is ... dresses retailer, has unveiled its new selection of evening dresses. ... shopping platform. Customers can view more at its ... been accepted and praised by customers for many years. It ... clients. In order to expand its market share, the company ...
(Date:12/19/2014)... print component of Vision and Hearing is distributed within ... with a circulation of approximately 230,433 copies and an ... nationally through a vast social media strategy and across ... To explore the digital version of the campaign, ... exclusive interview with Mark DeMontis , sharing his experience ...
(Date:12/19/2014)... intestinal bacteria that cause inflammatory bowel disease, which includes ... report. The findings, published recently in the journal ... prevent the disease and treat the 1.6 million Americans ... "The intestinal bacteria, or ,gut microbiome, you develop at ... on your health for the rest of your life," ...
(Date:12/19/2014)... (HealthDay News) -- Potentially illness-causing E. coli bacteria were ... markets, according to a new study. Researchers checked ... 13 farmers markets in Los Angeles and Orange counties ... almost 150 samples tested, 24 percent were positive for ... to the researchers. Both types of bacteria can ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
Other TagsOther Tags